Abstract: With the continued mature of hybridoma technology for monoclonal antibody production and the rapid development of cancer immunotherapy, the bispecific antibodies based anti-tumor medicine have been used in clinical practice． Due to the special adjustability of its bispecific and functional properties, the bispecific antibodies medicine is now becoming a hot spot of cancer immunotherapy research with increasing importance in the tumor immunotherapy． The present paper aims to review the progress and latest developments in bispecific antibodies based immunotherapy in lung cancer, and discusses current achievements and future challenges as well．